Open Source Paradigm Could Swipe Biz From CROs: Beroe

Natalie Morrison | | September 27, 2012

Open source drug developers could swipe business from CROs in the drug discovery field, according to Beroe.

In a study – conducted for – research analyst Sudarsan Pakaravoor said a lull in innovation for rare and orphan indications has led vendors to seek more innovative ways to work with industry.

He said the traditional industry, made up of a series of contract research organisations (CROs) and vendors is too “fragmented” and therefore the discovery process is divided.

However “open source” drug discovery – by which a contractor buys a compound with little data, shares that data with a sponsor and then provides development services for a fee – could be a way to plug the gaps, Pakaravoor told us.